Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer

Hye‐Young Min(Seoul National University), Ho‐Young Lee(Seoul National University of Science and Technology)

Molecular Cancer

June 4, 2015

10.1186/s12943-015-0392-3

Cited by 47

Related Papers

Molecular targeted therapy for anticancer treatment

|Experimental & Molecular Medicine|2022|495

Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib

|Cancer Research|2006|336

Hypoxia-inducible Factor 1α and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer

|JNCI Journal of the National Cancer Institute|2005|97

Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1–mediated transcriptional events

|Blood|2011|75

Effects of Insulin-like Growth Factor Binding Protein-3 and Farnesyltransferase Inhibitor SCH66336 on Akt Expression and Apoptosis in Non-Small-Cell Lung Cancer Cells

|JNCI Journal of the National Cancer Institute|2004|74